Literature DB >> 21320233

Tips and traps analyzing pediatric PK data.

Brian J Anderson1, Nick H G Holford.   

Abstract

Pharmacokinetic (PK) and pharmacodynamic (PD) modeling has elucidated aspects of developmental pharmacology of value to the anesthetic community. The increasing sophistication of modeling techniques is associated with pitfalls that may not be readily apparent to readers or investigators. While size and age are considered primary covariates for PK models, the impact of birth on clearance maturation is poorly documented, dose in obese children is poorly investigated, pharmacologic implications of physiologic changes poorly portrayed, disease progression on drug response poorly depicted and the impact of metabolites on effect poorly illustrated. This review identifies some of these pitfalls and suggests ideas to circumvent or investigate these hazards.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21320233     DOI: 10.1111/j.1460-9592.2011.03536.x

Source DB:  PubMed          Journal:  Paediatr Anaesth        ISSN: 1155-5645            Impact factor:   2.556


  55 in total

1.  Obesity and its impact on drug therapy: are we ready for this change?

Authors:  Michael Neely; Stan Louie
Journal:  Clin Pharmacokinet       Date:  2011-12-01       Impact factor: 6.447

2.  Designing a Pediatric Study for an Antimalarial Drug by Using Information from Adults.

Authors:  Caroline Petit; Vincent Jullien; Adeline Samson; Jérémie Guedj; Jean-René Kiechel; Sarah Zohar; Emmanuelle Comets
Journal:  Antimicrob Agents Chemother       Date:  2015-12-28       Impact factor: 5.191

3.  Serum levels of daptomycin in pediatric patients.

Authors:  C Antachopoulos; E Iosifidis; K Sarafidis; F Bazoti; E Gikas; A Katragkou; V Drossou-Agakidou; E Roilides
Journal:  Infection       Date:  2012-01-21       Impact factor: 3.553

4.  Multicenter-Based Population Pharmacokinetic Analysis of Ciclosporin in Hematopoietic Stem Cell Transplantation Patients.

Authors:  Ling Xue; Wen-Juan Zhang; Ji-Xin Tian; Lin-Na Liu; Hai-Hong Yan; Wen-Wen Zhang; Xiao-Liang Ding; Jing-Jing Zhang; Li-Yan Miao
Journal:  Pharm Res       Date:  2019-12-23       Impact factor: 4.200

5.  Population Pharmacokinetic Model of Sublingual Buprenorphine in Neonatal Abstinence Syndrome.

Authors:  Chee M Ng; Erin Dombrowsky; Hopi Lin; Michelle E Erlich; David E Moody; Jeffrey S Barrett; Walter K Kraft
Journal:  Pharmacotherapy       Date:  2015-07-14       Impact factor: 4.705

6.  Population pharmacokinetic and pharmacodynamic model of propofol externally validated in children.

Authors:  Byung-Moon Choi; Hyun-Gu Lee; Hyo-Jin Byon; Soo-Han Lee; Eun-Kyung Lee; Hee-Soo Kim; Gyu-Jeong Noh
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-02-28       Impact factor: 2.745

7.  Why standards are useful for predicting doses.

Authors:  Nick H G Holford; Brian J Anderson
Journal:  Br J Clin Pharmacol       Date:  2017-02-02       Impact factor: 4.335

8.  Developmental Pharmacokinetics and Age-Appropriate Dosing Design of Milrinone in Neonates and Infants with Acute Kidney Injury Following Cardiac Surgery.

Authors:  Tomoyuki Mizuno; Katja M Gist; Zhiqian Gao; Michael F Wempe; Jeffrey Alten; David S Cooper; Stuart L Goldstein; Alexander A Vinks
Journal:  Clin Pharmacokinet       Date:  2019-06       Impact factor: 6.447

9.  The integration of allometry and virtual populations to predict clearance and clearance variability in pediatric populations over the age of 6 years.

Authors:  Andrea N Edginton; Bhavank Shah; Michael Sevestre; Jeremiah D Momper
Journal:  Clin Pharmacokinet       Date:  2013-08       Impact factor: 6.447

10.  Development of a pharmacokinetic-guided dose individualization strategy for hydroxyurea treatment in children with sickle cell anaemia.

Authors:  Min Dong; Patrick T McGann; Tomoyuki Mizuno; Russell E Ware; Alexander A Vinks
Journal:  Br J Clin Pharmacol       Date:  2016-02-05       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.